10-K Filing

BIO-PATH HOLDINGS, INC. CIK: 1133818 FY 2019

Filing Information

Form Type	10-K
Accession Number	`0001104659-20-029711`
Period End Date	20191231
Filing Date	20200305
Fiscal Year	2019
Fiscal Period	FY
XBRL Instance	bpth-20191231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 59 Income Statement 20 Cash Flow Statement 45 Stockholders Equity 14

Balance Sheet 59 line items

Line Item	Tag	Value	Unit	Period
Preferred Stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred Stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred Stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred Stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Cash	`Cash`	$20.43M	USD	Point-in-time
Preferred Stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred Stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Cash	`Cash`	$1.00M	USD	Point-in-time
Prepaid drug product for testing	`PrepaidExpenseCurrent`	$776.00K	USD	Point-in-time
Preferred Stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Prepaid drug product for testing	`PrepaidExpenseCurrent`	$332.00K	USD	Point-in-time
Preferred Stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$803.00K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$788.00K	USD	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Total current assets	`AssetsCurrent`	$2.14M	USD	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$21.99M	USD	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	680,000.00	shares	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	3.69M	shares	Point-in-time
Furniture, fixtures & equipment	`PropertyPlantAndEquipmentGross`	$1.03M	USD	Point-in-time
Furniture, fixtures & equipment	`PropertyPlantAndEquipmentGross`	$998.00K	USD	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	680,000.00	shares	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	3.69M	shares	Point-in-time
Less accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$726.00K	USD	Point-in-time
Less accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$592.00K	USD	Point-in-time
Property, Plant and Equipment, Net	`PropertyPlantAndEquipmentNet`	$303.00K	USD	Point-in-time
Property, Plant and Equipment, Net	`PropertyPlantAndEquipmentNet`	$406.00K	USD	Point-in-time
Right of use operating assets	`OperatingLeaseRightOfUseAsset`	-	USD	Point-in-time
Right of use operating assets	`OperatingLeaseRightOfUseAsset`	$367.00K	USD	Point-in-time
Total Assets	`Assets`	$2.54M	USD	Point-in-time
Total Assets	`Assets`	$22.66M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$486.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$587.00K	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$673.00K	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$740.00K	USD	Point-in-time
Current portion of lease liabilities	`OperatingLeaseLiabilityCurrent`	$85.00K	USD	Point-in-time
Current portion of lease liabilities	`OperatingLeaseLiabilityCurrent`	-	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.24M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.33M	USD	Point-in-time
Noncurrent lease liabilities	`OperatingLeaseLiabilityNoncurrent`	-	USD	Point-in-time
Noncurrent lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$330.00K	USD	Point-in-time
Total Liabilities	`Liabilities`	$1.57M	USD	Point-in-time
Total Liabilities	`Liabilities`	$1.33M	USD	Point-in-time
Preferred stock, $.001 par value; 10,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, $.001 par value; 10,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, $.001 par value; 200,000 shares authorized; 3,692 and 680 shares issued and outstanding, respectively	`CommonStockValue`	$4.00K	USD	Point-in-time
Common stock, $.001 par value; 200,000 shares authorized; 3,692 and 680 shares issued and outstanding, respectively	`CommonStockValue`	$1.00K	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$77.42M	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$48.96M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-56.34M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-47.74M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$8.07M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$1.22M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$21.09M	USD	Point-in-time
Total Liabilities & Shareholders' Equity	`LiabilitiesAndStockholdersEquity`	$22.66M	USD	Point-in-time
Total Liabilities & Shareholders' Equity	`LiabilitiesAndStockholdersEquity`	$2.54M	USD	Point-in-time

Income Statement 20 line items

Line Item	Tag	Value	Unit	Period
Research and development	`ResearchAndDevelopmentExpense`	$4.60M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$4.58M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$3.38M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$4.11M	USD	Annual
Impairment of technology license	`ImpairmentOfIntangibleAssetsFinitelived`	-	USD	Annual
Impairment of technology license	`ImpairmentOfIntangibleAssetsFinitelived`	$608.00K	USD	Annual
Total operating expenses	`OperatingExpenses`	$8.69M	USD	Annual
Total operating expenses	`OperatingExpenses`	$8.59M	USD	Annual
Net operating loss	`OperatingIncomeLoss`	$-8.69M	USD	Annual
Net operating loss	`OperatingIncomeLoss`	$-8.59M	USD	Annual
Interest income	`InvestmentIncomeInterest`	$7.00K	USD	Annual
Interest income	`InvestmentIncomeInterest`	$94.00K	USD	Annual
Total other income	`NonoperatingIncomeExpense`	$7.00K	USD	Annual
Total other income	`NonoperatingIncomeExpense`	$94.00K	USD	Annual
Net loss	`NetIncomeLoss`	$-8.60M	USD	Annual
Net loss	`NetIncomeLoss`	$-8.58M	USD	Annual
Net loss per share, basic and diluted (in dollars)	`EarningsPerShareBasicAndDiluted`	$-14.38	USD	Annual
Net loss per share, basic and diluted (in dollars)	`EarningsPerShareBasicAndDiluted`	$-3.24	USD	Annual
Basic and diluted weighted average number of common shares outstanding	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	597,000.00	shares	Annual
Basic and diluted weighted average number of common shares outstanding	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	2.66M	shares	Annual

Cash Flow Statement 45 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-8.60M	USD	Annual
Net loss	`NetIncomeLoss`	$-8.58M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$684.00K	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$554.00K	USD	Annual
Amortization of technology license	`AmortizationOfIntangibleAssets`	$161.00K	USD	Annual
Amortization of technology license	`AmortizationOfIntangibleAssets`	-	USD	Annual
Amortization of right of use assets	`OperatingLeaseRightOfUseAssetsAmortization`	$96.00K	USD	Annual
Amortization of right of use assets	`OperatingLeaseRightOfUseAssetsAmortization`	-	USD	Annual
Depreciation	`Depreciation`	$265.00K	USD	Annual
Depreciation	`Depreciation`	$134.00K	USD	Annual
Impairment of technology license	`ImpairmentOfIntangibleAssetsFinitelived`	-	USD	Annual
Impairment of technology license	`ImpairmentOfIntangibleAssetsFinitelived`	$608.00K	USD	Annual
Prepaid drug product for testing	`IncreaseDecreaseInPrepaidExpense`	$444.00K	USD	Annual
Prepaid drug product for testing	`IncreaseDecreaseInPrepaidExpense`	$-785.00K	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$450.00K	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-15.00K	USD	Annual
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$536.00K	USD	Annual
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-168.00K	USD	Annual
Lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$79.00K	USD	Annual
Lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	-	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-6.12M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-8.36M	USD	Annual
Purchases of furniture, fixtures & equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	-	USD	Annual
Purchases of furniture, fixtures & equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$17.00K	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-17.00K	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	-	USD	Annual
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$1.18M	USD	Annual
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$900.00K	USD	Point-in-time
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$1.50M	USD	Point-in-time
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$26.70M	USD	Annual
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$17.00M	USD	Point-in-time
Net proceeds from exercise of warrants	`ProceedsFromStockOptionsExercised`	-	USD	Annual
Net proceeds from exercise of warrants	`ProceedsFromStockOptionsExercised`	$1.08M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$27.78M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$1.18M	USD	Annual
Net increase (decrease) in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$19.42M	USD	Annual
Net increase (decrease) in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-4.96M	USD	Annual
Cash, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$5.96M	USD	Point-in-time
Cash, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$20.43M	USD	Point-in-time
Cash, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.00M	USD	Point-in-time
Cash, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$5.96M	USD	Point-in-time
Cash, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$20.43M	USD	Point-in-time
Cash, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.00M	USD	Point-in-time
Addition to leasehold improvements	`NonCashLeaseholdImprovements`	$31.00K	USD	Annual
Addition to leasehold improvements	`NonCashLeaseholdImprovements`	-	USD	Annual

Stockholders Equity 14 line items

Line Item	Tag	Value	Unit	Period
Beginning Balance	`StockholdersEquity`	$8.07M	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$1.22M	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$21.09M	USD	Point-in-time
Issuance of common stock, net of fees	`StockIssuedDuringPeriodValueNewIssues`	$26.70M	USD	Annual
Issuance of common stock, net of fees	`StockIssuedDuringPeriodValueNewIssues`	$1.18M	USD	Annual
Issuance of common stock, net of fees	`StockIssuedDuringPeriodValueNewIssues`	$1.70M	USD	Point-in-time
Exercise of warrants, net of fees	`StockIssueDuringPeriodValueWarrantsExercised`	$1.08M	USD	Annual
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalOther`	$684.00K	USD	Annual
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalOther`	$554.00K	USD	Annual
Net loss	`NetIncomeLoss`	$-8.60M	USD	Annual
Net loss	`NetIncomeLoss`	$-8.58M	USD	Annual
Ending Balance	`StockholdersEquity`	$8.07M	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$1.22M	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$21.09M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.